We assessed the empirical Bayes geometric mean (EBGM) and its lower bound (EB05) of the relative reporting ratio for MACE among DPP-4i reports in the full FAERS database and in a subset of reports limited to cardiovascular and diabetic drugs. We then compared the EB05 in these 2 analyses and calculated the percent positive agreement for signals of disproportional reporting (SDRs) involving MACE.
| INTRODUCTION
As of 2015, the Centers for Disease Control and Prevention estimate that 23.1 million people in the United States have diagnosed diabetes, 5% of whom have type 1 diabetes. 1 Many of these patients also experience medical complications such as coronary heart disease, stroke, nephropathy, neuropathy, and retinopathy. 2 . 5 The breakdown of GLP-1 stimulates the release of insulin, improving glucose homeostasis. DPP-4i
have several appealing characteristics including a low risk of hypoglycemia as well as the absence of an association with weight gain or gastrointestinal symptoms that often limit the use of other antidiabetic products. Based on premarketing clinical trial data, adverse events are less severe than other treatment options but include acute pancreatitis. 6 In addition, DPP-4i were initially thought to protect against major adverse cardiac events (MACE), making them a safer option to rosiglitazone and other thiazolidinediones, which have been linked to heart failure. 7, 8 However, while failing to reach statistical significance, one phase 4 trial suggested hospitalization for heart failure with saxagliptin use. 9 Given continued interest in the cardiovascular safety of these products on the part of patients, clinicians, payers, and regulators, we compared signals for disproportional reporting (SDRs) for MACE for DPP-4i in the full set of drug-related FDA adverse event reports
and a subset containing all of the adverse event reports for cardiovascular and diabetic drug products.
| METHODS

| Data
We used postmarketing adverse event data submitted to the FDA 
| Rationale of datasets and analytic approach
We conducted Bayesian disproportionality analyses using 2 different sets of data. We use the full set of drug-related adverse event reports in FAERS ("full set") and a subset of reports submitted only for noninsulin antihyperglycemic agents and drugs indicated for cardiovascular disease ("cardiovascular subset"). By using these 2 different sets, we were able to compare and contrast SDR between 2 datasets with different assumptions regarding the Bayesian prior for the disproportionality analysis. In the overall body of FAERS reports, the Bayesian prior comprised of the general patient population and therefore assumed average risk for MACE. In the cardiovascular subset, the Bayesian prior assumed a higher risk for the patient population in that they were known to have diabetes or cardiovascular disease by virtue of the drugs they were on. In each dataset, we also compared the EB05 for DPP-4i to those of sulfonylureas and biguanides. We compared the results of DPP-4i with sulfonylureas due to their known cardiovascular risk, 12 high utilization, and similar patient population to DPP-4i patients. We chose biguanides as a second comparison group due to their relatively low cardiovascular risk. 
| Analysis
We first characterized the patients for whom adverse event reports
were submitted for DPP-4i, sulfonylureas, and biguanides in both the full set and cardiovascular subset.
KEY POINTS
• The US Food and Drug Administration issued a warning for heart failure risk in diabetics with the use of dipeptidyl peptidase-4 inhibitors (DPP-4i) based on underpowered, post hoc analyses of clinical trials.
• We conducted Bayesian disproportionality analyses on adverse event reports to assess whether DPP-4i elicited signals of disproportional reporting (SDRs) for cardiovascular events in the full set of adverse event reports and among a subset implicating cardiovascular and diabetic drugs.
• We found 2 SDRs for heart failure among DPP-4i.
Additionally, the cardiovascular subset elicited more SDRs for cardiovascular events than the full dataset.
• Our findings support the current Food and Drug
Administration warning of heart failure risk with the use of DPP-4i.
We conducted disproportionality analyses on every drug-event combination in the full dataset to determine the empirical Bayes geometric mean (EBGM) of the relative reporting ratio. For our cardiovascular subset of reports, we filtered the full dataset for all reports for suspect drugs that were FDA approved oral antihyperglycemic agents or cardiovascular medications listed in Table   S1 . From the cardiovascular subset, we conducted the DuMouchel disproportionality analysis on each drug-event combination to determine the EB05. In this analysis, the oral antihyperglycemic agents and cardiovascular drugs served as the Bayesian prior. We then assessed the percent positive agreement for the signals for MACE between the cardiovascular subset and the full set of reports.
Finally, we compared the disproportionality results of MACE reporting for DPP-4i, sulfonylureas, and biguanides for the cardiovascular set and the full set of reports. We also calculated the percent positive agreement between signals for MACE with DPP-4i, sulfonylureas, and biguanides in the full dataset and the cardiovascular subset.
To determine whether or not reporting of MACE was sensitive to regulatory actions related to oral antihyperglycemic agents, we assessed the possibility of stimulated reporting of adverse events with DPP-4i using the methods previously described by Hoffman et al. 20 We first identified three actions that could have potentially stimulated To assess whether these actions resulted in an increase in reporting,
we then compared the period after these actions to the period after sham actions. We chose sham action dates 5 fiscal quarters prior to the regulatory actions.
For each of the regulatory actions and sham actions, we calculated the percent change in the number of reports in the 2 quarters after the regulatory and sham actions and performed a Mann-Whitney test to assess statistically significant differences in percent change between the pairs.
This study was exempt from review by a Johns Hopkins University Institutional Review Board.
3 | RESULTS
| Descriptive statistics
There were a total of 180.4 million drug-event pairs in the full dataset and 13.4 million (7.4%) in the cardiovascular subset. (Tables S2 to S4 ).
| Full FAERS dataset
| Report subset with diabetes and cardiovascular drugs
Similar to the full dataset, the subset of reports from cardiovascular drugs had a signal for myocardial infarction with alogliptin (EB05 = 4. Excludes products with n = 0 reports, EB05 <0, or EBGM <0.
However, the following sulfonylurea-containing products elicited a signal for congestive heart failure: glipizide (EB05 = 23.7), and (Tables S2 to S4 ).
| Comparison of SDR by dataset
There were 2 signals for MACE in the Bayesian disproportionality analysis of the full dataset compared to 12 with the cardiovascular subset among DPP-4i (Table 1) Table 2 shows the percent positive agreement between the full dataset and the cardiovascular subset for DPP-4i, sulfonylureas, and biguanides, respectively. Of the 14 MACE of interest, 5 had a percent positive agreement ≥50%, suggesting that surveillance for a subset of reports from patients who may be at heightened risk of MACE has utility in detecting additional SDR. Among the reports from patients who may be expected to experience MACE, there was greater detection of congestive heart failure, atrioventricular block complete, cerebrovascular accident, and cerebral infarction. The lowest percent positive agreement was with arteriosclerosis coronary artery, sudden death, and cerebrovascular accident each with 0% percent positive agreement. Heart failure (PPA = 33.3%) and congestive heart failure (percent positive agreement (PPA) = 33.3%) each had low percent positive agreement.
| Percent positive agreement between full set and cardiovascular set
The analyses of the full dataset and the cardiovascular subset each detected 12 unique SDRs.
| Stimulated reporting
Comparing the percent change between the 2 months after the regu- 
| DISCUSSION
In this disproportionality analysis of FDA adverse event reports, we examined the relative reporting ratio for MACE with the use of DPP-4i. Among a subset of adverse events reports that are generated from a group of patients with a high risk for cardiovascular events, there was an increase in reporting of MACE for sitagliptin, saxagliptin, linagliptin, and alogliptin. These SDRs suggest that even among a group of reports where one would expect to see high numbers of reports for these events, the DPP-4i class stands out. In addition to the previously reported association with heart failure, our results suggest that DPP-4i adverse event reporting is increased for multiple MACE. Finally, we found that creating a subset of reports from drugs associated with diabetes and cardiovascular disease allowed for detection of additional MACE reporting.
Interestingly, our analyses of the cardiovascular risks of DPP-4i using the full FAERS dataset only identified 2 SDRs, whereas our use of the cardiovascular subset elicited 12 distinct signals. By contrast, we identified fewer cardiovascular signals using the full rather than the subset when examining sulfonylureas (20 vs 10) and biguanides (8 vs 9) . This suggests that for products where there is a known association with cardiovascular events with those products (ie, sulfonylureas), signal detection in the full FAERS dataset is sensitive enough to detect potential SDR. However, for products where association is tenuous, a subset with reports from a high-risk patient population may be more sensitive to capture additional SDR for further investigation.
As the purpose of disproportionality analyses is hypothesis generation, this evidence cannot independently support FDA actions. While prior evidence suggested that DPP-4i were associated with heart failure, we were interested in investigating whether or not there were additional SDRs for other MACE with distinct pathogenesis (eg, myocardial infarction). In examining percent positive agreement between analyses of the 2 datasets, the cardiovascular subset can allow for greater sensitivity to detect SDR associations that might be confounded by comorbidities commonly found with diabetes. This methodology of subsetting the adverse event reports to a high-risk pool of patients has utility in identifying SDR for further investigation.
Our approach of honing in on a subset of adverse events reports from similar drugs or a high-risk population provides opportunities for increasing the sensitivity of Bayesian signal detection. Given that signal detection methods are primarily used by regulatory agencies for hypothesis generation about drug safety issues, increasing sensitivity is desirable especially in cases where comorbidities may act like confounders. In this example, we were able to highlight additional MACE aside from heart failure that could be further investigated in longitudinal studies. This method allows for increased vigilance for specific risk groups without the high resource allocation an FDA Risk Evaluation and Mitigation Strategies program would require.
The FDA has acknowledged the limitations of its current signal detection methods and is actively seeking novel approaches to its surveillance activities. Two points of concern with current practices are the threshold of EB05 = 2.0 and residual confounding. 24 Through restriction of the Bayesian prior to adverse event reports stemming from a pool of patients with related illnesses, our approach can reduce the level of residual confounding. Additionally, as the EB05 = 2.0 threshold is considered a minimal threshold for further investigation of a drug safety concern, regulators can adjust this threshold based on the restricted patient population and their unique health concerns.
For instance, if this analysis approach were applied to a subset of reports associated with oncology products, regulators might increase the threshold for action on a non-life-threatening adverse event.
Our study had several limitations. The FAERS dataset is primarily a case report dataset initially developed to detect drug-drug interactions. 25 In this study, we were mining the data for single-drug adverse 
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